Many studies over the past decade have together identified genes that are recurrently mutated in the myelodysplastic syndromes (MDS). We will summarize how this information has informed our understanding of disease pathogenesis and behavior, with an emphasis on how this information may inform therapeutic strategies.
INTRODUCTION
The myelodysplastic syndromes (MDS) exemplify the heterogeneous nature of myeloid malignancies, both in their clinical behavior and underlying disease biology. In recent years, advances in genomic sequencing technologies have allowed for the identification of a plethora of somatic mutations in MDS that have yielded immense insight into disease biology. Moreover, many newly identified disease alleles are associated with disease phenotypes and clinical outcomes. Nevertheless, the incorporation of molecular genetic information into diagnostic and prognostic algorithms has yet to enter routine clinical practice, and novel therapies based on this information remain lacking. Herein we review recent advances in our understanding of the molecular genetics of MDS, with a particular focus on how these advances may directly influence clinical practice and novel therapeutic strategies.
Epigenetic modifiers
Aberrant DNA methylation has long been observed as a feature of MDS that may be predictive of prognosis and disease progression [1] [2] [3] [4] [5] [6] [7] , and therapy with DNA-methyltransferase inhibitors such as 5-azacytidine and decitabine can effect robust clinical responses [8] [9] [10] . Thus, it is not surprising that epigenetic modifiers have been found to be among the most commonly recurrently mutated genes in MDS.
In 2009, high-resolution single nucleotide polymorphism and comparative genomic hybridization arrays were utilized to identify in patients with myeloid malignancies a minimally deleted region on chromosome 4q24 encompassing TET2 [11] . Subsequent targeted sequencing studies identified TET2 mutations in 19-26% of MDS cases [12] [13] [14] [15] . Simultaneously, TET2 was discovered to have a function in the conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) [16] , leading to subsequent demethylation of DNA [17] [18] [19] , providing a link between these mutations and aberrant methylation.
A frame-shift mutation in DNMT3A was identified in a re-analysis of the first sequenced acute myeloid leukemia (AML) genome [20] , and subsequent analyses of MDS patients identified DNMT3A mutations at a frequency ranging from 3-13% of cases [21] [22] [23] [24] . The presence of DNMT3A in nearly all of the cells of the bone marrow of MDS patients [22] suggests its role as a founding mutation, further bolstered by recent studies implicating DNMT3A as a pre-leukemic mutation [25,26 & ,27]. Sequencing of another AML genome identified a mutation in IDH1 [28] , with subsequent targeted sequencing identifying IDH1 and IDH2 mutations in 4-12% of MDS patients [23, 29, 30] . These mutations were discovered to confer a neomorphic function to IDH1/2, whereby they produce the oncometabolite 2-hydroxyglutarate, which appears to directly impair hematopoietic differentiation [31, 32] . 2-hydroxyglutarate inhibits a number of epigenetic modifiers including TET2 [33] and histone demethylases [33, 34] , thereby linking these mutations with the epigenetic machinery.
Analyses of focal deletions on chromosome 7q and 20q led to the discovery of somatic EZH2 [35, 36] and ASXL1 [37] mutations in 6-12% [24, 35, 38 ] and 14-21% [37] [38] [39] [40] [41] of MDS patients, respectively. EZH2 is a member of the polycomb repressive complex 2, which is responsible for methylation of lysine 27 on histone 3 (H3K27), which is associated with transcriptional repression. ASXL1 has been demonstrated to associate with polycomb repressive complex 2 and recruit it to target loci, with deletion leading to derepression of particular genes such as the HOXA cluster [42] .
Spliceosome mutations
In 2011, a whole exome sequencing study demonstrated recurrent mutations of the splicing factor SF3B1 in 20% of MDS patients [43] , with a particularly high frequency in disease characterized by ringed sideroblasts (65%). Subsequent whole exome and whole genome sequencing efforts revealed mutations in other splicing factors including U2AF1 [44] , ZRSR2, and SRSF2 [45] , with splicing pathway mutations being present in 45-85% of all MDS cases. Mutations in the splicing machinery occurred in a mutually exclusive manner, suggesting a common mechanism of action, and mutations appeared to affect recognition of the 3' splice acceptor site on introns, promoting altered pre-mRNA splicing. A mouse model expressing the mutant Srsf2P95H allele promoted myelodysplasia and altered the preference of SRSF2 for exonic splicing enhancer motifs, leading to the expression of an altered isoform of Ezh2 that undergoes nonsense-mediated decay [46 && ], in part explaining how altered mRNA splicing may contribute to alterations in hematopoiesis. Similarly, expression of U2af1S34F in an inducible transgenic mouse model led to alterations in splicing of RNA processing genes, ribosomal genes, and a number of genes recurrently mutated in MDS and AML [47 && ].
Other mutations
Although mutations in epigenetic modifiers and splicing factors comprise the most commonly observed recurrent mutations in MDS, many less frequent mutations encompass distinct classes of genes such as 
KEY POINTS
Comprehensive sequencing efforts have identified a variety of molecular genetic abnormalities in MDS that in part explain the heterogeneous biology and clinical behavior of these disorders.
Molecular genetic abnormalities in MDS may be predictive of disease phenotypes, including prognosis and response to therapy, but their utility in the clinic is limited given already robust clinical prognostic algorithms and few effective therapies for MDS.
Particular molecular genetic abnormalities themselves represent promising therapeutic targets, with a number of ongoing pre-clinical and clinical studies testing novel compounds that may target these abnormalities.
stem and progenitor cells with reduced ribosome biogenesis, increased stress resistance, and a competitive advantage with respect to wild-type hematopoietic stem and progenitor cells [49 & ], recapitulating several hallmarks of MDS.
Refining prognostic models with molecular genetic abnormalities
The use of clinical prediction tools such as the International Prognostic Scoring System (IPSS) [50] , developed in 1997, has long allowed clinicians to use parameters such as bone marrow blast percentage and cytogenetic abnormalities to counsel patients and inform treatment decisions. In 2012, a revised IPSS (IPSS-R) scoring system was established, incorporating an expanded set of chromosomal abnormalities and age, as well as measurements of cytopenias and excess blasts weighted based on severity [51] .
Although none of the established prognostic scoring systems to date have incorporated molecular genetic abnormalities, many prior studies have suggested a potential role for particular gene mutations in refining prognostic models. For example, prior analyses of TP53 [52] , DNMT3A [22] , ASXL1 [37, 39] , IDH1 [53] , and SRSF2 [54] [55] [56] [57] mutations found associations with poor prognosis. However, such analyses largely assessed single genes in isolation and may have incompletely determined the independent contributions of mutated genes in the context of complex genotypes. To address this, Bejar and colleagues sequenced 111 cancer-associated genes in 439 patients with MDS, identifying ASXL1, RUNX1, TP53, EZH2, and ETV6 as independent predictors of poor overall survival in a multivariate analysis controlling for IPSS classification [38] . The large number of patients surveyed also allowed for the identification of genotype/phenotype correlations, such as the association of RUNX1, TP53, and NRAS mutations with severe thrombocytopenia and an elevated blast percentage, and the association of TP53 mutations with complex karyotypes. Such clinical associations may in part explain how the prognostic impact of such mutations is indirectly captured by the IPSS.
A subsequent study by Papaemmanuil and colleagues performed targeted sequencing of 111 genes across 738 patients with MDS, identifying driver mutations in 43 genes [48] . Of note, 36 of these genes were in a 'long tail' of genes mutated in less than 5% of all patients, but in aggregate, these rare mutations comprised 33.5% of all mutations, underscoring the significant mutational heterogeneity of MDS. Although this study corroborated the poor prognostic import of genes such as ASXL1, RUNX1, and TP53, as well as SRSF2 and U2AF1 (not included in the study by Bejar and colleagues), it also identified a correlation between the absolute number of driver mutations present and decreased leukemiafree survival. Whether or not the detected mutations were clonal or subclonal did not impact their prognostic import, suggesting that use of sensitive sequencing techniques to identify small subclones will be needed to maximize the clinical potential of identifying these mutations. However, utilizing a clinical data set incorporating all available standard clinical variables, the addition of molecular genetic data contributed only a marginal non-significant increase in prognostic value. Given the 'long tail' of infrequently mutated genes in MDS, further studies in larger cohorts of MDS patients (such as the ongoing IPSS-R Mol.) may be necessary to derive more robust prognostic schema utilizing molecular genetics. However, at the current time the extent to which molecular genetics can improve on existing clinical risk stratification schema remains unresolved, which is in part a testament to the robustness of prognostic algorithms developed by astute clinicians.
The contribution of molecular genetic abnormalities to understanding the origin and clonal evolution of the myelodysplastic syndromes
The finding of MDS-associated cytogenetic abnormalities in hematopoietic stem cells (HSCs) purified from MDS patient bone marrows has long suggested that MDS is initiated in this primitive cell population [58] [59] [60] . More recent studies have demonstrated that essentially all recurrent somatic mutations observed in low-risk MDS are acquired in HSCs [61] . This stands in contrast to AML, in which the full complement of mutations is not acquired in HSCs, but rather a more committed myeloid progenitor, with a subset of mutations found in functionally normal 'pre-leukemic' HSCs [26 & ,27] ( Fig. 1 ). Many mutations found in preleukemic HSCs are also recurrently mutated in MDS (e.g., DNMT3A, TET2, and ASXL1), and when MDS progresses to AML, additional mutations are likely acquired in MDS progenitors [61, 62] . A critical question then is what distinguishes a normally functioning 'pre-leukemic' HSC from an MDS HSC that gives rise to ineffective hematopoiesis. The fact that many healthy older adults may exhibit clonal hematopoiesis with MDS-associated mutations, such as DNMT3A, TET2, and ASXL1 [63 && ,64 && ], suggests that more than one mutation is required to produce MDS. Analysis of the allelic frequencies of mutations in large sequencing datasets [48] is beginning to shed light on the order of acquisition of mutations in MDS, but further functional studies using animal models will be necessary to determine the minimal complement of mutations necessary to give rise to MDS. Targeting MDS stem cells that harbor this minimal complement of mutations will be a necessary feature of any novel therapy capable of inducing durable disease remissions. The order of acquisition of mutations itself may have prognostic significance, as has recently been demonstrated for myeloproliferative neoplasms harboring both TET2 and JAK2 mutations [65 & ].
Diagnostic utility of molecular genetics
The diagnosis of MDS remains challenging, particularly in cases without obvious morphologic dysplasia, excess blasts, or abnormal cytogenetics. This has led to the development of terms such as idiopathic cytopenias of unknown significance (ICUS) [66] . Molecular genetic abnormalities may provide evidence for clonal hematopoiesis and allow for reclassification of some cases of ICUS to low-risk MDS, but designating all patients with ICUS and an MDS-associated mutation inappropriately presumes causality and will almost certainly lead to overdiagnosis. As multiple mutations are likely to be necessary to develop MDS, more comprehensive sequencing of patients with ICUS with prospective clinical follow-up will be necessary to establish what combinations of mutations are specific for fully penetrant disease.
Selecting patients for transplantation
Although allogeneic transplantation is the only potentially curative therapeutic modality for MDS, its potential morbidity and mortality need to be balanced with an assessment of disease risk. Indeed, a Markov decision analysis of a large MDS transplant registry suggested that immediate transplantation of patients with lower-risk disease may lead to worse outcomes [67] . Molecular genetics may help to identify patients with lower-risk MDS that actually have higher disease risk and who may benefit from early transplantation. To identify such a subgroup, Bejar and colleagues sequenced 22 genes in 288 patients with lower-risk MDS, finding EZH2, RUNX1, TP53, and ASXL1 to be associated with worse outcomes [24] . However, in a multivariate analysis incorporating all other clinical data, only EZH2 mutations retained independent prognostic significance. Thus, similar to the study by Papaemmanuil and colleagues discussed above, the marginal contribution of molecular genetic data to prognostication independent of other clinical data remains limited. Ultimately, the most relevant question is whether allogeneic transplantation can modify the outcome of poor-risk molecular genetics, as has been demonstrated for some AML genotypes [68] . Particular mutations such as those in TP53 and TET2 predict for such a poor outcome even after allogeneic transplantation [69 && ] that the value of transplantation in such patients remains questionable. Such patients might then be targeted for novel non-transplant therapies, intensified conditioning regimens, and/or post-transplant prophylaxis strategies. An examination of molecular genetics in prospective trials, such as an ongoing CIBMTR trial comparing outcomes with allogeneic transplant versus hypomethylating agent therapy or best supportive care, will be necessary to fully assess the ability of transplantation to overcome the poor risk conferred by high-risk molecular genetic abnormalities.
Predicting disease response to conventional therapies
Mutations in TET2 and DNMT3A may predict for an increased likelihood of response to hypomethylating agents [70,71 & ,72], but this predictive value is modest, does not correlate with improved survival, and does not influence clinical management in the absence of an alternative first-line therapy for MDS. Moreover, a recent study examining the response of patients with chronic myelomonocytic leukemia to decitabine was unable to confirm these associations, but rather found that DNA methylation profiles at diagnosis may be highly predictive of response ). GDF11 appears to be overexpressed in MDS and is also associated with aging [85], but it is unclear if it is enriched in any particular MDS subtype. As such, these therapies, along with almost all other novel therapies being investigated, are not targeted toward any specific molecular genetic subgroup. One exception is the use of IDH1/2 inhibitors in highrisk MDS patients with IDH mutations, which have demonstrated impressive response rates as single agents [86 & ]. Inhibitors of the splicing machinery are currently in early phase trials for chronic lymphocytic leukemia (CLL) [87 & ,88] and appear to exhibit selective toxicity to MDS cells in pre-clinical models [89] [90] [91] ; they represent a promising therapy that might benefit a significant percentage of patients given the prevalence of splicing mutations in MDS. Comprehensive sequencing of patients treated with novel therapies not targeted towards any particular subgroup may help to identify molecular genetic subgroups most likely to benefit from such therapies and lend insight into disease biology and therapeutic mechanisms. An instructive example is the longstanding observation of robust clinical responses to lenalidomide in patients with del(5q)-associated MDS [74], which recently led to significant insights into how lenalidomide modulates the degradation of a haploinsufficient gene on chromosome 5q (CSNK1A1) to deplete MDS cells in a synthetic lethal manner [92 && ], revealing a novel therapeutic paradigm that may be applied to many other cancers.
CONCLUSION
The past decade has witnessed significant advances in our understanding of the molecular underpinnings of MDS, helping to explain its heterogeneous clinical presentation and behavior. However, already robust existing clinical prediction tools and a meager therapeutic armamentarium limit the utility of molecular genetic abnormalities in prognostication and influencing therapeutic decisions (summarized in Table 1 ). Perhaps an area of most immediate impact may be the ability of molecular genetics to identify patients with low-risk disease by clinical parameters who may have a higher risk for disease progression. Whether allogeneic transplantation can overcome the high risk conferred by such molecular genetic abnormalities will need to be addressed in ongoing prospective trials. We will undoubtedly continue to discover new molecular genetic abnormalities and potentially 'druggable' targets through ongoing sequencing efforts. Together, these advances promise to bring our now vast knowledge of the molecular genetics of 27:617-630. The study described a mouse model in which the mutant Srsf2P95H allele was conditionally expressed. This promoted morphologic dysplasia, whereas loss of SRSF2 function did not, suggesting that SRSF2 mutations have an altered function that promotes disease. Accordingly, the authors observed alterations in the preference of Srsf2P95H for exonic splicing enhancer motifs, leading to an altered isoform of EZH2 that undergoes nonsense mediated decay, explaining how altered splicing might alter the function of other genes implicated in hematopoiesis. This also explains the mutual exclusivity between SRSF2 and EZH2 mutations in MDS.
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